85-2072-62　［取扱停止］EBP1 Inhibitor, WS6 (N-(6-(4-(2-(4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenylamino)-2-oxoethyl)phenoxy)pyrimidin-4-yl)cyclopropanecarboxamide, xHCl, Erb3 Binding Protein-1 Inhibitor, IKK Inhibitor XV, PA2G4 Inhibitor) 10mg　217333

特徴

• A cell-permeable phenoxypyrimidin-cyclopropanecarboxamide compound that effectively stimulates the growth of primary beta cells in cultured primary rat and human islets in vitro (ECmax in 4 d = 200 and 400nM, respectively) and in the murine type 1 diabetes (T1D) model RIP-DTA in vivo (170% of control pancreas Ki-67-positive beta cells in 1 wk; 5mg/kg i.p. q.o.d.) by interacting with IKKε and EBP1/PA2G4/Erb3 binding protein-1 and blocking the known suppressor function of EBP1 toward E2F-mediated transcription. Likewise, dual inhibition of EBP1 (with shRNA) and IKK (1uM) is shown to fully recapitulate the proliferating effect of WS6 in R7T1 cells.
• Alternate Names:Erb3 Binding Protein-1 Inhibitor, IKK Inhibitor XV, PA2G4 Inhibitor, N-(6-(4-(2-(4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenylamino)-2-oxoethyl)phenoxy)pyrimidin-4-yl)cyclopropanecarboxamide, xHCl
• Molecular Formula:C₂₉H₃₁F₃N₆O₃ • xHCl
• Solubility:DMSO or H2O
• Primary Target:EBP1/PA2G4/Erb3 binding protein-1
• Secondary Target:IKK epsilon
• Storage and Stability:Store at -20°C under inert atmosphere. For maximum recovery of product, centrifuge the original vial prior to removing the cap.